Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis - 14/05/14
, Soo-Yong Tang, FRCPath, DPhil, Alistair Robson, FRCPath, DipRCPath, Stephen Morris, MRCP, FRCR, Nita Agar, MBBS (Hons), FACD, PhD, E. Mary Wain, MD, FRCP, Fiona Child, MRCP, MD, Julia Scarisbrick, FRCP, Michael Neat, BSc (Hons), Sean Whittaker, MD, FRCPAbstract |
Background |
The t(14;18)(q32;q21) chromosomal translocation is found in the majority of nodal follicular lymphomas but only rarely in primary cutaneous follicle center cell lymphomas (PCFCL). Recent studies have postulated that the translocation is more prevalent in PCFCL than previously described and that it might be a molecular prognostic marker.
Objectives |
The purpose of our study was to analyze cases of PCFCL for the presence of a t(14;18) translocation using fluorescence in situ hybridization to detect balanced translocations involving either the BCL2 or MALT1 loci and to correlate the results with growth pattern, immunophenotype, and clinical outcome.
Method |
In all, 57 patients with PCFCL were extracted from our cutaneous lymphoma database. Retrospective analysis of clinical parameters including lesion type, location, diagnostic stage, lactate dehydrogenase, initial treatment, relapse rate, and survival was performed.
Results |
In all, 57 patients with PCFCL were included in this study. We detected 1 BCL2 chromosomal amplification, 4 translocations of BCL2, and 1 IGH/MALT1 translocation.
Limitations |
This was a case series retrospective study.
Conclusions |
PCFCL has an excellent 5-year overall survival (100% disease-specific survival). Chromosomal abnormalities of either BCL2 or MALT1 were detected in 10% of cases but do not correlate with a specific immune pathology or clinical outcome.
Le texte complet de cet article est disponible en PDF.Key words : B-cell lymphoma, BCL2 translocation, disease-free survival, fluorescence in situ hybridization, primary cutaneous follicle center cell lymphoma, t(14;18) translocation
Abbreviations used : bcl, EORTC, FISH, PCFCL, PCR, WHO
Plan
| Supported by the United Kingdom National Institute for Health Research Biomedical Research Center based at Guy's and St Thomas' National Health Service Foundation Trust. |
|
| Conflicts of interest: None declared. |
Vol 70 - N° 6
P. 1010-1020 - juin 2014 Retour au numéro
Article précédent
- Cutaneous extranodal natural killer/T-cell lymphoma: A comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site
- Woo Jin Lee, Joon Min Jung, Chong Hyun Won, Sung Eun Chang, Jee Ho Choi, Kee Chan Moon, Chan-Sik Park, Jooryung Huh, Mi Woo Lee
- Histiocytoid Sweet syndrome may indicate leukemia cutis: A novel application of fluorescence in situ hybridization
- Rahul N. Chavan, Mark A. Cappel, Rhett P. Ketterling, David A. Wada, Nicole M. Rochet, Ryan Knudson, Lawrence E. Gibson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?